OncLive TV

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the management of patients with sarcoma.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the use of chemoimmunotherapy in patients with non–small cell lung cancer (NSCLC).

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses sequencing therapies in the treatment of patients with pancreatic cancer.

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses results of the Abi Race study for patients with metastatic castration-resistant prostate cancer.

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses managing immune-related adverse events (irAEs) in patients with non–small cell lung cancer (NSCLC).

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses immunotherapy in the context of precision medicine in lung cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses microsatellite instability and mismatch repair deficiency as potential biomarkers in endometrial cancer.

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses sequencing therapy for patients with hepatocellular carcinoma.

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses important factors of deciding which patients with breast cancer need axillary lymph node dissection.

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the adoption of genetic testing into routine clinical practice.

Richard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.